Escalation of Commiement in Software Projects: An Examination of Two Theories

Escalation of commitment is common in many software projects. It stands for the situation where managers decide to continue investing in or supporting a prior decision despite new evidence suggesting the original outcome expectation will be missed. Escalation of commitment is generally considered to be irrational. Past literature has proposed several theories to explain the behaviour. Two commonly used interpretations are self-justification and the framing effect. While both theories have been found effective in causing the escalation of commitment, their relative effect is less studied. The purpose of this study is to further investigate the primary factor that causes the escalation of commitment in software project related decisions. An experiment was designed to examine whether the escalation of commitment exists in different decision contingencies and which theories play a more important role in the escalation. One hundred and sixty two subjects participated in the experiment. The results indicate that both self-justification and problem framing have effects on commitment escalation in software projects but the effect of self-justification is stronger. Significant interaction effect is also found. A commitment is more likely to escalate if the problem is framed positively

Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer

AbstractStatins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR) inhibitors decreasing serum cholesterol and have shown promise in cancer prevention. In this study, we demonstrated the oncogenic role of HMGR in colorectal cancer (CRC) by disclosing increased HMGR activity in CRC patients and its enhancement of anti-apoptosis and stemness. Our previous studies showed that statins containing carboxylic acid chains possessed activity against histone deacetylases (HDACs), and strengthened their anti-HDAC activity through designing HMGR-HDAC dual inhibitors, JMF compounds. These compounds exerted anti-cancer effect in CRC cells as well as in AOM-DSS and ApcMin/+ CRC mouse models. JMF mostly regulated the genes related to apoptosis and inflammation through genome-wide ChIP-on-chip analysis, and Ingenuity Pathways Analysis (IPA) predicted their respective regulation by NR3C1 and NF-κB. Furthermore, JMF inhibited metastasis, angiogenesis and cancer stemness, and potentiated the effect of oxaliplatin in CRC mouse models. Dual HMGR-HDAC inhibitor could be a potential treatment for CRC

Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden

Poorly differentiated pancreatic neuroendocrine carcinomas (NECs) are rare and aggressive malignancies with rapid disease progression and early widespread metastasis. Given histology similarity, they are commonly treated with platinum-based chemotherapy as small cell lung cancer (SCLC). However, no standard treatment has been established for recurrent or progressive disease. We present an Asian patient with recurrent poorly differentiated pancreatic NEC after curative surgery and adjuvant chemotherapy with cisplatin and etoposide. The tumor mutational burden (TMB) was high. The patient received chemotherapy combined with maintenance immunotherapy with nivolumab and achieved promising and durable response, suggesting TMB could be a biomarker to identify NEC patients for immune checkpoint inhibitor (ICI) treatment

Combined Merkel Cell Carcinoma with Nodal Presentation: Report of a Case Diagnosed with Excisional but Not Incisional Biopsy and Literature Review

Merkel cell carcinoma (MCC) is a rare primary neuroendocrine carcinoma (NEC) of the skin. As compared to pure MCCs, combined MCCs are aggressive and exhibit a higher probability of metastasis. A correct diagnosis might be missed, especially when the biopsy sample is too small or too superficial. We report a 79-year-old Taiwanese male who presented with lymphadenopathy suspicious for lymphoma. A nodal biopsy showed metastatic NEC. A skin tumor in the lower back was identified, and an incisional biopsy showed only squamous cell carcinoma (SCC). A subsequent excisional biopsy was performed based on the advice of the senior pathologist because of the presence of metastatic nodal NEC. Finally, a diagnosis of combined MCC and SCC was confirmed. Our literature review identified 13 cases of combined MCC with nodal metastasis as initial presentations, all with an aggressive clinical course. Both the MCC and non-MCC components could be present in the metastatic nodes. Metastases of pure MCC cells were observed in three combined MCCs in sun-protected areas, probably pointing to a distinct pathogenesis. Excision or punch biopsy to include the deep dermal NEC component is recommended as timely diagnosis is mandatory for appropriate management of patients with this rare skin cancer

Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden

Poorly differentiated pancreatic neuroendocrine carcinomas (NECs) are rare and aggressive malignancies with rapid disease progression and early widespread metastasis. Given histology similarity, they are commonly treated with platinum-based chemotherapy as small cell lung cancer (SCLC). However, no standard treatment has been established for recurrent or progressive disease. We present an Asian patient with recurrent poorly differentiated pancreatic NEC after curative surgery and adjuvant chemotherapy with cisplatin and etoposide. The tumor mutational burden (TMB) was high. The patient received chemotherapy combined with maintenance immunotherapy with nivolumab and achieved promising and durable response, suggesting TMB could be a biomarker to identify NEC patients for immune checkpoint inhibitor (ICI) treatment

No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer

Abstract This study aimed to compare survival of patients with advanced major salivary gland cancers treated with adjuvant chemoradiation therapy (CRT) versus radiotherapy (RT) alone, after surgical resection. The Taiwan Cancer Registry database was used to identify patients (2009–2017) with advanced (T3–4 or nodal positivity) major salivary gland cancers, treated post-surgically with adjuvant CRT or RT alone. Overall survival (OS) and disease-specific survival (DSS) evaluated using Kaplan–Meier. Stratified analyses conducted on clinicopathological features. A total of 395 patients were analyzed: 178 (45.1%) received adjuvant CRT; 217 (54.9%) received adjuvant RT alone. Median radiation dose was 66 Gy in 33 fractions. Cisplatin was most common chemotherapy regimen. After a median follow-up of 3.37 years, there was no significant difference in OS or DSS (p = 0.1354 and 0.3361, respectively) between groups. Adding chemotherapy to adjuvant RT was not significantly associated with improved OS (adjusted hazard ratio [aHR] 0.94; 95% CI 0.72–1.23) and DSS (aHR 0.96; 95% CI 0.72–1.28). Stratified analysis of clinicopathological features found no significant advantages for improved OS or DSS from adding chemotherapy to adjuvant RT. Thus, in this population database, the use of chemotherapy provided limited survival benefits in advanced major salivary gland cancers after surgical resection

Health Effects of Medical Radiation on Cardiologists Who Perform Cardiac Catheterization

We investigated the health effects of low-dose radiation on cardiologists exposed to scattered radiation while performing cardiac catheterization (CC) in a hospital setting from 2003 to 2006. Methods: We performed a 4-year retrospective study on 2, 292 medical doctors, using claims data from all contracted hospitals of the Bureau of National Health Insurance, Taiwan. We gathered statistical data regarding radiation-related diseases using the International Classification of Diseases, 9th Revision, Clinical Modification record numbers of each doctor. Results: Of the 2,292 doctors evaluated, 1,721 were aged 35–50 years and the remaining 571 were aged 51–65 years. There were 892 cardiologists who performed CC (experimental group), and the majority of these (733/892, 82.17%) were aged 35–50 years. There were 1,400 medical doctors who performed no CC from 2003 to 2006 (control group). A total of 988 of these belonged to the 35–50 years age group and 412 to the 51–65 years group. In the 35–50 years group, the controls had significantly more medical visits for hematological and thyroid cancer (p <0.05), skin disease (p <0.001), and acute upper respiratory tract infection (p <0.001) compared with the experimental group. In contrast, cardiologists who performed catheterization had more cataracts compared with the control group, but this difference was not significant. Conclusion: Doctors who did not perform CC had more visits for radiation-related diseases than those who performed catheterization. In the experimental group, cardiologists aged 35–50 years who were exposed to radiation during CC had more visits for cataracts than the control group. We recommend that radiation protection concepts be emphasized to cardiologists, and that hospital managers be obligated to upgrade angiography equipment because the newer models have less scattered radiation

Primary hepatic diffuse large B-cell lymphoma with favorable response to immunochemotherapy

Primary hepatic lymphoma (PHL) is a tumor confined to the liver without involvement of the spleen, lymph nodes, or bone marrow. It is an extremely rare malignancy, accounting for only 0.0016% of non-Hodgkin lymphoma worldwide. Generally, a liver biopsy is required to make a diagnosis of PHL due to the lack of specific clinical manifestations, biochemical indicators, and image features. However, there is currently a lack of consensus on the standard treatment of PHL. Chemotherapy can be an effective treatment due to the tumor's chemosensitivity. Herein, we report a 78-year-old male with a confirmed diagnosis of primary hepatic diffuse large B-cell lymphoma via liver biopsy. We treated the patient with immunochemotherapy using Rituximab-COP combination. The tumor had a favorable response, without recurrence for over a three-year period of follow-up. Even though the reported median survival of PHL is 15 months, appropriate treatment can provide a chance for sustained remission

Suppression of hydrodynamic sloshing in liquefied natural gas tank with floating baffle: Experimental and numerical studies

A fixed anti-sloshing mechanism such as baffles which modifies the tank structure may lead to increment of the maintenance cost. This paper proposes a floating baffle, and reviews its investigation on the sloshing behaviour in a membrane-type tank model under unidirectional excitation with 30% and 50% of filling ratio. An LNG tank was numerically simulated in OpenFOAM under regular sinusoidal motion with an amplitude of 3 cm and excitation frequency set to the natural frequency at 1.1 seconds. Impulsive pressure on the tank wall was obtained, and then benchmarked with the experimental results from the pressure sensors. The simulation and experiment results showed an acceptable agreement with a root mean squared error of less than 10%. The findings are expected to become a significant reference for safer sea transportations such as conventional LNG vessels

Roundabout Guidance Receptor 1 Is an Emerging Prognostic Biomarker for Nasopharyngeal Carcinoma

Background: Nasopharyngeal carcinoma (NPC) is a malignant tumor originating from the nasopharynx with high morbidity and mortality in Southeast Asia and south of China. Roundabout guidance receptor 1 (ROBO1) can regulate axonogenesis (axon-like protrusion), which may play an important role in migration. However, the roles of ROBO1 in NPC have not been clarified. Methods: A comparative analysis employing the NPC transcriptome (GSE12452) and the axonogenesis-related genes (GO: 0050772) was performed. In total, 124 tissue blocks from patients primarily diagnosed as NPC (1993-2002) were examined using immunohistochemical staining. The connections between clinicopathological variables and protein immunoexpression were analyzed by Pearson’s chi-square test. The Kaplan–Meier method with a log-rank test was employed to plot survival curves. Multivariate analysis was performed using the Cox proportional hazards model to identify independent prognostic biomarker. Results: According to transcriptome analysis, we found that ROBO1 is significantly highly expressed in NPC tissues compared with normal tissues. The immunohistochemistry (IHC) staining showed that high expression of ROBO1 was significantly related to primary tumor (T1T2 and T3T4) ( P  = .024), nodal metastasis status (N0N1 and N2N3) ( P  = .030), stage (I-II and III-IV) ( P  = .019), and histological grade (keratinizing, non-keratinizing, and undifferentiated) ( P  = .065). Importantly, NPC patients with high ROBO1 expression had poorer disease-specific survival (DSS) ( P  = .0001), distal metastasis-free survival (DMeFS) ( P  < .0001), and local recurrence-free survival (LRFS) ( P  = .0001) compared with NPC patients with low ROBO1 expression through the uni-/multivariate and the Kaplan–Meier survival analyses. Conclusion: Our report indicates that ROBO1 might be a potential prognostic biomarker for NPC